In "Major Banks," China International Capital Corporation (CICC) stated that the acquisition of SINO BIOPHARM could enhance the layout in the weight loss metabolism field, maintaining a target price of 8.9 yuan

CICC's research report indicates that SINO BIOPHARM (01177.HK) announced a 1.2 billion RMB acquisition of 100% of Hejia Bio. Hejia Bio focuses on the siRNA sector, with a key emphasis on three major chronic disease areas: weight loss metabolism, cardiovascular and cerebrovascular, and nervous system. Its core platform possesses differentiated competitive advantages.

The firm believes that existing therapies in the chronic disease field generally face issues such as limited efficacy, safety risks, and low patient compliance, leading to a significant unmet clinical demand. This acquisition is expected to help SINO BIOPHARM build a next-generation cardiovascular treatment innovation pipeline and enhance its layout in the weight loss metabolism field. Additionally, the company's comprehensive R&D system and sales channels are likely to expedite Hejia Bio's clinical progress and subsequent commercialization, with both parties expected to achieve synergistic win-win outcomes.

The firm maintains its adjusted net profit forecasts for 2025 and 2026 at 4.47 billion RMB and 4.921 billion RMB, respectively, and introduces a forecast for 2027 at 5.423 billion RMB; it maintains a target price of HKD 8.9 and an "outperform industry" rating